STOCK TITAN

United Therapeutics Corporation to Present at the UBS Biopharma Conference 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) announced that Patrick Poisson, EVP, Technical Operations, will provide an overview and update on the company's business at the UBS Biopharma Conference 2023. The session will be held on November 8, 2023, and can be accessed via a live webcast on the United Therapeutics website. An archived version will be available for 180 days.
Positive
  • None.
Negative
  • None.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.,--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the UBS Biopharma Conference 2023 in Miami Beach, Florida.

The session will take place on Wednesday, November 8, 2023, from 10:00 a.m. to 10:25 a.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 180 days.

United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/pbc.

Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 31, 2023 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Dewey Steadman at (202) 919-4097

https://ir.unither.com/contact-uthr/

Source: United Therapeutics Corporation

Patrick Poisson, Executive Vice President, Technical Operations.

UBS Biopharma Conference 2023 in Miami Beach, Florida.

Wednesday, November 8, 2023, from 10:00 a.m. to 10:25 a.m., Eastern Standard Time.

Via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations.

Yes, an archived version will be available approximately 24 hours after the session ends and can be accessed for 180 days.
United Therapeutics Corp

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Silver Spring

About UTHR

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians